Overall verdict
Buy
6.8/10
1-year performance
—
Score breakdown
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 0.0/10.
Hyperliquid Strategies Inc. operates as a digital asset treasury company in the United States. It focuses on building, managing, and optimizing HYPE tokens, which are the native digital assets of the Hyperliquid Layer-1 blockchain. The company is headquartered in New York, New York.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
David Schamis
Founded
2025
Employees
5
Revenue / employee
1.9M USD
Next earnings
February 4, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC1.77%
- Bank of New York Mellon Corp0.21%
- Rest of the register98.02%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
—
52-week low
—
1-year performance
—
Year-to-date performance
153.68%
Position in the 52-week range
—
Range: 17.00 USD - 35.00 USD (2 methods agree)
Net margin 4327.7%, ROIC 55.2%, ROE 55.2%.
Net margin
4327.69%
Exceptional
Sector -14.06%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
55.24%
Exceptional
Sector -18.81%|S&P 17.06%
Return on invested capital (ROIC)
55.24%
Exceptional
Free cash flow margin (FCF)
-166.77%
Negative
Profit-to-cash conversion (FCF conversion)
-0.04x
Low
Revenue to net income
Revenue (trailing 12 months)
21.7M USD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
-58.33%
Sharply revised down
Valuation
6.4/10P/E 2.8x, forward P/E 3.0x, EV/EBITDA 13094.4x.
P/E (TTM)
2.8x
Cheap
Sector 32.5x|S&P 23.6x
Forward P/E
3.0x
Cheap
EV / EBITDA
—
N/A
Sector 17.2x|S&P 15.5x
PEG
—
Sector 0.13|S&P 0.91
Fair value (reverse DCF)
19.00 USD
Deeply undervalued
Market cap
2.5Md USD
Financial strength
10.0/10no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-7.48%
Net cash
Cash
255M USD
Cash / market cap
10.26%
Solid
Net debt
-255M USD
Equity
3.4Md USD
Closed daily candles, 11 months
Last close on November 10, 2026: 8.75 USD
- MM209.53
- MM5011.10
- MM2007.86
- RSI 1441.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+8.79%
50-day average slope, 1 month
+3.45%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
7.93 % per day
Volatility change
+24.35%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 3.00 (3) | 0.14 (1) | 62 (3) | — | 748 (3) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PURR | 6.8 | 6.8 | 2.5Md USD | 2.8x | 4327.7 % | — | 55.2 % | — | -1.5 % | — | ||
| 2 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 3 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 6 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
